MACROGENICS, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
MACROGENICS, INC. (MGNX) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of -$448.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2026-03-09
- MACROGENICS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2025 was -$448.00K, a 103.71% decline from fiscal 2024.
- MACROGENICS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2024 was $12.08M, a 281.38% increase from fiscal 2023.
- MACROGENICS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2023 was $3.17M, a 30.66% decline from fiscal 2022.
- MACROGENICS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2022 was $4.57M, a 55.39% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month |
|---|---|
| 2025-12-31 | -$448.00K 10-K · filed 2026-03-09 |
| 2024-12-31 | $12.08M 10-K · filed 2026-03-09 |
| 2023-12-31 | $3.17M 10-K · filed 2026-03-09 |
| 2022-12-31 | $4.57M 10-K · filed 2025-03-20 |
| 2021-12-31 | $10.24M 10-K · filed 2024-03-07 |
| 2020-12-31 | $14.69M 10-K · filed 2023-03-15 |
| 2019-12-31 | $5.83M 10-K · filed 2022-02-24 |
| 2018-12-31 | $8.47M 10-K · filed 2021-02-25 |
| 2017-12-31 | $8.46M 10-K · filed 2020-02-25 |
| 2016-12-31 | $2.55M 10-K · filed 2019-02-26 |
| 2015-12-31 | $3.30M 10-K · filed 2018-02-27 |
| 2014-12-31 | $2.23M 10-K · filed 2017-02-28 |
| 2013-12-31 | $226.00K 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |